Companion animal diabetes affects approximately 1 in 300 dogs and 1 in 230 cats, with prevalence rising as obesity rates increase. The diabetes management market generated approximately $400 million in 2025. Merck Animal Health's Vetsulin (porcine insulin) is the leading veterinary insulin product. Zoetis's ProZinc (PZI insulin) targets feline diabetes. Continuous glucose monitoring — Abbott's FreeStyle Libre (off-label) and emerging veterinary-specific devices — is transforming diabetes management from periodic curve testing to continuous data. Emerging GLP-1 receptor agonist research and oral hypoglycemics expand the therapeutic pipeline.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Companion Animal Diabetes Market Size, Growth and Forecast 2025-2030
• Canine Diabetes Mellitus — Disease Burden and Treatment
• Feline Diabetes Mellitus — Distinct Pathophysiology and Treatment
• Veterinary Insulin Products — Vetsulin, ProZinc, Caninsulin
• Continuous Glucose Monitoring — FreeStyle Libre and Veterinary Devices
• Periodic Glucose Curve Testing and In-Clinic Monitoring
• GLP-1 Receptor Agonist Research in Veterinary Medicine
• Oral Hypoglycemics and Emerging Therapeutics
• Therapeutic Diet Co-Prescription for Diabetes Management
• Owner Compliance and Long-Term Disease Management
Table of Contents
1. Executive Summary
2. Market Overview
3. Companion Animal Diabetes Market Size, Growth and Forecast 2025-2030
4. Canine Diabetes
5. Feline Diabetes
6. Veterinary Insulin Products
7. Continuous Glucose Monitoring
8. Periodic Curve Testing
9. GLP-1 Receptor Agonist Research
10. Oral Hypoglycemics
11. Therapeutic Diet Co-Prescription
12. Owner Compliance
13. Market Challenges and Risks
14. Competitive Landscape
15. Strategic Conclusions and Recommendations
16. Appendix
List of Tables
Table 1. Companion Animal Diabetes Market Size and Forecast 2025-2030
Table 2. Disease Prevalence by Species and Risk Factor
Table 3. Veterinary Insulin Sales by Brand 2023-2025
Table 4. CGM Adoption in Veterinary Medicine
Table 5. Glucose Curve Testing Volume by Practice
Table 6. GLP-1 Pipeline Activity by Supplier
Table 7. Oral Hypoglycemic Pipeline
Table 8. Therapeutic Diet Co-Prescription Rates
Table 9. Owner Compliance Rates by Therapeutic Approach
Table 10. Competitive Positioning by Therapeutic Category
Companies Profiled
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Dechra Pharmaceuticals
Elanco Animal Health
Merck Animal Health
Vetoquinol
Virbac
Zoetis
